New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
16:00 EDTNAVBNavidea reduces R&D expense to less than $20M for 2014
In a regulatory filing, Navidea Biopharmaceuticals disclosed that on June 16, in a conference call, Dr. Michael Goldberg, Interim CEO of Navidea Biopharmaceuticals, stated that, as a result of the previously announced reorganization plan to reduce the company’s cash burn, the company’s previous 2014 research and development expense guidance of between $25M to $30M is being reduced to less than $20M for the calendar year.
News For NAVB From The Last 14 Days
Check below for free stories on NAVB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NAVB

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use